| Literature DB >> 22926307 |
Yong-Kun Wang1, Jiang Han, Wu-Jun Xiong, Qiong-Ying Yuan, Yan-Ping Gu, Jun Li, Zhe Zhu, Hui Zhang, Cong-Jun Wang.
Abstract
Oxidative stress is involved in the development and progression of disease. Because sodium aescinate has been reported to have immunity enhancing and antioxidative effects, we investigated its activity by employing a hepatocellular carcinoma (HCC) mouse model. Sixty BALB/c mice were randomly divided into four groups, including a 1.4 mg/kg treated group (n = 15), a 2.8 mg/kg treated group (n = 15), an untreated hepatocellular carcinoma control group (n = 15) and a normal control group (n = 15). After H22 cells were cultured for one week, we collected 2 × 10⁶ cells and injected them subcutaneously as 0.2 mL cell suspensions in sterile saline into the right shoulder region of every mouse. The animals were monitored for changes in activity, physical condition and body weight during the experiment. The next day after injection of H22 cells, animals in these test groups received one intraperitoneal injection of drug or physiological saline for 13 days. Results showed that in the sodium aescinate injection liquid (SAIL)-treated HCC mice, serum interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), Gamma-glutamyltransferase (γ-GT), alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) levels were significantly decreased compared with normal control mice. In addition, treatment with sodium aescinate injection liquid significantly decreased blood and liver malondialdehyde (MDA) levels, increased glutathione (GSH) levels, and antioxidant enzyme [superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)] activities in a dose-dependent manner. We conclude that sodium aescinate injection liquid can decrease oxidative injury and enhance immunity functions in HCC mice.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22926307 PMCID: PMC6268365 DOI: 10.3390/molecules170910267
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Sodium aescinate injection liquid affecting tumour inhibition rate.
| Group | Tumour weight (g) | Inhibition rate (%) |
|---|---|---|
| I | - | - |
| II | 1.47 ± 0.13 | - |
| III | 1.18 ± 0.12 d | 20.07 |
| IV | 1.01 ± 0.09 d | 31.83 |
d p < 0.01, compared with group II. I: normal control group; II: untreated model control (HCC) group; III: HCC + sodium aescinate injection liquid (1.4 mg/kg b.w.) group; IV: HCC + sodium aescinate injection liquid (2.8 mg/kg b.w.) group.
Sodium aescinate injection liquid affecting serum IL-1β, IL-6, TNF-α, and IFN-γ levels.
| Group | IL-1β (pg/mL) | IL-6 (pg/mL) | TNF-α (pg/mL) | IFN-γ (pg/mL) |
|---|---|---|---|---|
| I | 115.28 ± 9.49 | 209.43 ± 19.57 | 3.76 ± 0.33 | 32.38 ± 2.48 |
| II | 154.03 ± 13.18 b | 286.27 ± 24.08 b | 7.03 ± 0.49 b | 41.27 ± 3.88 b |
| III | 133.51 ± 10.39 d | 241.96 ± 22.15 d | 5.29 ± 0.41 d | 38.46 ± 3.45 c |
| IV | 118.19 ± 9.99 d | 215.27 ± 17.83 d | 4.17 ± 0.32 d | 34.93 ± 2.67 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II. I: normal control group; II: untreated model control (HCC) group; III: HCC + sodium aescinate injection liquid (1.4 mg/kg b.w.) group; IV: HCC + sodium aescinate injection liquid (2.8 mg/kg b.w.) group.
Sodium aescinate injection liquid affecting serum γ-GT, ALT, AST and ALP levels.
| Group | γ-GT (U/100 mL) | ALT (U/L) | AST (U/L) | ALP (U/L) |
|---|---|---|---|---|
| I | 2.74 ± 0.18 | 60.32 ± 5.39 | 94.81 ± 7.82 | 80.35 ± 5.38 |
| II | 10.75 ± 1.22 c | 102.69 ± 8.49 b | 140.27 ± 10.58 b | 139.28 ± 11.29 b |
| III | 7.23 ± 0.57 d | 83.19 ± 6.02 d | 129.71 ± 11.03 c | 115.03 ± 10.01 c |
| IV | 5.38 ± 0.42 d | 72.17 ± 6.11 d | 114.38 ± 9.37 d | 97.36 ± 6.82 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II. I: normal control group; II: untreated model control (HCC) group; III: HCC + sodium aescinate injection liquid (1.4 mg/kg b.w.) group; IV: HCC + sodium aescinate injection liquid (2.8 mg/kg b.w.) group.
Sodium aescinate injection liquid affecting serum and liver MDA, GSH, SOD, CAT and GSH-Px levels.
| Group | MDA | GSH | SOD | CAT | GSH-Px | |
|---|---|---|---|---|---|---|
| I | serum | 4.28 ± 0.27 | 173.14 ± 12.84 | 261.33 ± 18.04 | 48.03 ± 2.81 | 55.28 ± 4.44 |
| liver | 3.37 ± 0.27 | 152.85 ± 13.65 | 216.42 ± 18.48 | 49.02 ± 3.01 | 41.39 ± 3.33 | |
| II | serum | 8.57 ± 0.71 b | 90.21 ± 7.03 b | 150.28 ± 12.25 b | 22.16 ± 1.94 b | 33.21 ± 2.73 b |
| liver | 8.02 ± 0.71 b | 98.27 ± 8.02 b | 163.15 ± 13.29 b | 21.47 ± 1.69 b | 23.07 ± 2.01 b | |
| III | serum | 6.44 ± 0.54 d | 136.21 ± 10.37 d | 197.24 ± 14.81 d | 35.19 ± 2.69 d | 42.09 ± 2.88 d |
| liver | 6.81 ± 0.53 d | 130.22 ± 11.26 d | 188.22 ± 14.06 d | 31.77 ± 1.52 d | 30.82 ± 2.31 d | |
| IV | serum | 5.25 ± 0.43 d | 155.73 ± 13.22 d | 257.13 ± 22.04 d | 42.83 ± 3.01 d | 51.37 ± 3.53 d |
| liver | 4.62 ± 0.35 d | 148.91 ± 12.53 d | 204.15 ± 17.39 d | 43.05 ± 3.57 d | 38.04 ± 2.86 d | |
b p < 0.01, compared with group I; d p < 0.01, compared with group II. I: normal control group; II: untreated model control (HCC) group; III: HCC + sodium aescinate injection liquid (1.4 mg/kg b.w.) group; IV: HCC + sodium aescinate injection liquid (2.8 mg/kg b.w.) group.